Results 11 to 20 of about 4,196 (141)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

Vaccines, 2021
The efficacy and safety of the BNT162b2 vaccine are known, but antibodies are expected to decrease over time after vaccination. We collected blood samples from 104 fully vaccinated health care workers at 3 and 5 weeks after first vaccination and 4 months
Dong Ho Jo, Dohsik Minn, Jaegyun Lim
exaly   +3 more sources

Effectiveness of the Pfizer-BioNTech Vaccine against COVID-19-Associated Hospitalizations among Lebanese Adults ≥75 Years Old—Lebanon, April–May 2021

Epidemiologia, 2023
In Lebanon, the nationwide vaccination against COVID-19 was launched in February 2021 using the Pfizer-BioNTech vaccine and prioritizing elderly people, persons with comorbidities, and healthcare workers.
Zeina Farah, Majd Saleh, Pamela Mrad
exaly   +3 more sources

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers

Medicina (Lithuania), 2021
Background and Objectives: This study aims to evaluate the effectiveness of the BNT162b2 COVID-19 (coronavirus disease 2019) in preventing severe symptomatic laboratory-confirmed infection among healthcare workers in a real-world scenario.
Efrén Murillo-Zamora, Xóchitl Trujillo, MIGUEL HUERTA   +2 more
exaly   +3 more sources

Benign Fasciculation Syndrome and Migraine Aura without Headache: Possible Rare Side Effects of the BNT162b2 mRNA Vaccine? A Case Report and a Potential Hypothesis

Vaccines, 2022
The BNT162b2 (Pfizer BioNTech) mRNA vaccine is an effective vaccine against COVID-19 infection. Here, we report an adverse event following immunization (AEFI) in a 48-year-old female patient who presented with fasciculations, migraine auras without ...
Grgur Salai, Ernest Bilic, Dragan Primorac   +2 more
exaly   +3 more sources

Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems

Pharmaceutics, 2022
The SARS-CoV-2 virus has caused a global crisis, resulting in 0.5 billion infections and over 6 million deaths as of March 2022. Fortunately, infection and hospitalization rates were curbed due to the rollout of DNA and mRNA vaccines.
Ahmed O. Shalash, Armira Azuar, Harrison Y. R. Madge, Naphak Modhiran, Alberto A. Amarilla, Benjamin Liang, Alexander A. Khromykh, Waleed M. Hussein, Keith J. Chappell, Daniel Watterson, Paul R. Young, Mariusz Skwarczynski, Istvan Toth   +12 more
doaj   +2 more sources

Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study

Vaccines, 2023
More than 600 healthcare workers died due to COVID-19 infection until January 2022 in Ecuador. Even though the COVID-19 vaccines are safe, local and systemic reactions were reported among physicians. This study aims to analyze the adverse events of COVID-
Josué Rivadeneira-Dueñas, Luis Fuenmayor-González, Tamara Otzen   +2 more
exaly   +3 more sources

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients

Journal of Hepatology, 2022
Ziv Ben Ari
exaly   +2 more sources

COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine [PDF]

International Journal of General Medicine
Abdallah Damin Abukhalil,* Raya Riyad Abushehadeh,* Sireen Sultan Shatat,* Ni’meh Al-Shami,* Hani A Naseef,* Hosniyeh Ladadweh,* Raed Madia* Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit ...
Abukhalil AD, Abushehadeh RR, Shatat SS, Al-Shami N, Naseef HA, Ladadweh H, Madia R   +6 more
doaj   +2 more sources

Local reactions to the second dose of the BNT162 COVID ‐19 vaccine [PDF]

Dermatologic Therapy, 2021
Multiple strategies have been implemented worldwide to fight the burden of the pandemic caused by COVID-19, with vaccination being one of the most promising.1 Notably, the first vaccine to be authorized in Italy was the BNT162 mRNA-based vaccine, which has also been approved in the USA, United Kingdom, and Canada.1,2 As a matter of fact, RNA vaccines ...
Tammaro A., Adebanjo G. A. R., Parisella F. R., De Marco G., Rello J.   +4 more
openaire   +4 more sources

Newly diagnosed pediatric immunoglobulin A nephropathy after vaccination against SARS-CoV-2: a case report [PDF]

Childhood Kidney Diseases, 2022
The messenger RNA-based vaccine for the coronavirus disease 2019 (COVID-19) may induce glomerulonephritis, including immunoglobulin A nephropathy (IgAN).
Do Young Kim, Hyung Eun Yim, Min Hwa Son, Kee Hwan Yoo   +3 more
doaj   +1 more source